Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pneumococcal vaccine
Biotech
Vaxcyte’s pneumococcal shot holds its own against Pfizer, Merck
Vaxcyte saw its stock jump after the biotech’s 31-valent pneumococcal vaccine went head-to-head with Prevnar 20 and Capvaxive in a phase 3 test.
James Waldron
Oct 5, 2026 8:41am
Pfizer ‘comfortable’ joining fights with hantavirus, Ebola: exec
May 20, 2026 5:05am
GSK's new CEO looking for $2B-$4B deals 'hiding in plain sight'
Feb 4, 2026 7:25am
GSK axes vaccine from $2.1B deal, switches to preclinical heir
Oct 30, 2024 7:06am
Vaxcyte surges on 'stunning' 31-valent PCV win against Pfizer
Sep 3, 2024 10:32am
Merck compares pneumococcal vaccine to 1983 warhorse
Apr 29, 2024 9:00am
